Examine how judicial directions have shaped health regulation in India, with reference to recent cases.

India's health regulation rests on scattered laws and executive codes. The Supreme Court reads the right to health into Article 21 and has repeatedly filled the gaps. It has done this in three ways: by recognising rights, by laying down interim rules, and by pushing the executive towards legislation.

1. Recognising rights and making them workable

• In Common Cause (2018), the Court recognised the right to die with dignity and laid down guidelines for advance medical directives (living wills) [5].
• In 2023, it found that procedure unworkable and simplified it itself [5]. In the absence of a statute, the Court keeps refining the rules it made.

2. Filling regulatory gaps on misleading health claims

• In IMA v. Union of India (the Patanjali case), petitioners invoked Article 32 against misleading claims about medicines [3].
• The Court's May 2024 order required advertisers to file a self-declaration before any advertisement runs. It declared this binding law under Article 141 [3]. The government applied it to all new advertisements from 18 June 2024 [4].

3. Pushing the executive towards statutory regulation of pharma marketing

• The Uniform Code for Pharmaceutical Marketing Practices (UCPMP) has operated since 2015 [2]. Its 2024 version bans gifts, monetary benefits and hospitality to doctors and their families [6].
• The code is still an executive instrument without statutory backing. On a petition by medical representatives (FMRAI) [2], the Court on 8 October 2026 directed the Centre to form an expert committee within two weeks. The committee must report within two months of its first meeting on statutory rules for pharma marketing [1].
• The Court sets deadlines but leaves lawmaking to Parliament, which respects the separation of powers.

Limitations

• Episodic: regulation moves case by case, only when someone petitions the Court.
• Dependent on the executive: results rest on government follow-through. The UCPMP's long run without statutory force shows this [1][2].
• Correction is slow: the 2023 revision of Common Cause came five years after the original guidelines [5].
• Risk of overreach: court-made rules can blur the line with legislative work.

Judicial directions have turned Article 21's promise into concrete norms on end-of-life care, health advertising and pharma ethics. They should remain a bridge, not a substitute. Parliament should codify these norms: a statutory marketing code with penalties for companies, and a clear law on advance directives. That would make the right to health enforceable and support SDG 3 (good health and well-being).